BCI is A small-molecule, allosteric inhibitor of DUSP6 (dual-specificity phosphatase 6) with IC50 of 12.3 uM; also inhibits human DUSP1 with IC50 of 11.5 uM; suppresses the ERK-induced activation of Dusp6 and regulates heart size in zebrafish.

A small-molecule, allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase (TrpAB).

A small-molecule, fumaric acid ester (FAE) compound that is a prodrug of methyl hydrogen fumarate (also known as monomethyl fumarate), for the treatment of relapsing-remitting multiple sclerosis and plaque psoriasis..

A small-molecule, orally active inhibitor of TNF-α that reduces replication of HIV-1 (IC50=300 nM) and Mycobacterium tuberculosis in human cells.

A sodium channel inhibitor..

PF-915275 is a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (Ki ＜ 1 nM) with good preclinical pharmacokinetic properties.IC50 value: ＜ 1 nM (Ki)[2]Target: 11βHSD1in vitro: PF-915275 maintains potency in our cellular assay against human 11βHSD1 (HEK293, EC50 = 5 nM) and is selective against human 11βHSD2 (HEK293, 1.5% inhibition 10 μM). PF-915275 displays only weak affinity for the rodent choline transporter (Ki = 9.6 μM) and the hamster melatonin MT3 receptor (Ki = 9.6 μM) in the Cerep Bioprint screening panel. PF-915275 has good in vitro pharmacokinetic properties. In particular, PF-915275 is categorized as a low clearance compound (liver microsome assays) with high permeability (Caco2 assay). [2]in vivo: As a prelude to in vivo studies with PF-915275, the rat pharmacokinetic properties of this compound were determined. PF-915275 has an excellent pharmacokinetic profile characterized by low clearance, long half-life and good oral bioavailability. [2]

A specific anti-respiratory syncytial virus (RSV) agent with EC50 of 0.2 uM in plaque reduction assays.

A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3.

A specific HIF asparaginyl hydroxylase (FIH) inhibitor with Ki of 83 uM, but not HIF prolyl hydroxylase (>1 mM).

A specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII.

A specific inhibitor of mitochondrial Na(+)-Ca(2+) exchanger (mNCE) with IC50 of 1.5 uM in INS-1 cells.

A specific p38 MAPK inhibitor with IC50 of 0.6 uM.

A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry..

A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry..

A specific, competitive inhibitor of 14-3-3/ligand interactions with high affinity.

A specific, irreversible inhibitor of MLK-related kinase MRK (ZAK), does not inhibit Bcr-Abl.

A specific, membrane-permeable inhibitor of Gq signaling.

A specific, non-competitive, small molecule cytochrome c oxidase (CcO or complex IV) inhibitor with IC50 of 18.93 uM (CcO from human glioma).

A specific, small molecule Bax agonist that promotes Bax-dependent but not Bak-dependent apoptosis.

A spirocyclic fungal natural product used in treatment of fungal dermatophytes..

A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase.

A staurosporine analog that promotes embryonic stem cell (ESC) differentiation by inhibiting nuclear localization of the MYC transcription factor NME2, which in turn results in down-regulation of MYC transcription.